Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report

Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.

Abstract

Important progress has been made in the management of Helicobacter pylori infection and in this fifth edition of the Maastricht Consensus Report, key aspects related to the clinical role of H. pylori were re-evaluated in 2015. In the Maastricht V/Florence Consensus Conference, 43 experts from 24 countries examined new data related to H. pylori in five subdivided workshops: (1) Indications/Associations, (2) Diagnosis, (3) Treatment, (4) Prevention/Public Health, (5) H. pylori and the Gastric Microbiota. The results of the individual workshops were presented to a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in the various clinical scenarios.

Keywords: GASTRITIS; HELICOBACTER PYLORI; HELICOBACTER THERAPY.

Publication types

  • Consensus Development Conference

MeSH terms

  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Bismuth / therapeutic use
  • Clarithromycin / therapeutic use
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination
  • Dyspepsia / microbiology
  • Early Detection of Cancer
  • Evidence-Based Medicine
  • Fluoroquinolones / therapeutic use
  • Gastritis / microbiology
  • Gastrointestinal Microbiome
  • Gastroscopy
  • Helicobacter Infections / complications
  • Helicobacter Infections / diagnosis*
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / prevention & control
  • Helicobacter pylori*
  • Humans
  • Microbial Sensitivity Tests
  • Nitroimidazoles / therapeutic use
  • Practice Guidelines as Topic
  • Proton Pump Inhibitors / therapeutic use*
  • Risk Factors
  • Stomach / microbiology
  • Stomach Neoplasms / diagnosis*
  • Stomach Neoplasms / microbiology

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Nitroimidazoles
  • Proton Pump Inhibitors
  • Amoxicillin
  • Clarithromycin
  • Bismuth